Abstract Number: 204

EASI-75 interpretation from a patient perspective – a phase 2b post-hoc analysis of dupilumab in adults with moderate-to-severe atopic dermatitis

N. Martin, Y. Poulin, S. Tyring, T. Kimura, M. Andria, E. Ghorayeb, L. Eckert, J. Chao

Meeting: 2017 Dermcoll

Session Information

Date: -

Session Title: Posters

Session Time: -

Objective: To assess the relationship between achieving 75% reduction from baseline in Eczema Area and Severity Index (EASI-75) and patient-reported burden in patients with moderate-to-severe atopic dermatitis (AD) in a dupilumab phase 2b trial (NCT01859988).

Methods: Patients received subcutaneous dupilumab 100 mg every 4 weeks (q4w), 300 mg q4w, 200 mg every 2 weeks (q2w), 300 mg q2w, 300 mg weekly (qw), or placebo for 16 weeks. This post-hoc analysis grouped patients based on EASI-75 achieved vs. not achieved status at Week 16 (W16), regardless of treatment arm. Patient-reported outcomes included peak pruritus Numerical Rating Scale (NRS), SCOring AD Visual Analogue Scale (SCORAD VAS) sleep loss, Dermatology Life Quality Index (DLQI), and missed days of work/school.

Results: Across all treatment arms, 180 patients achieved EASI-75 at W16 and 174 did not. Mean EASI scores (standard deviation) at W16 were 3.156(0.653) and 19.350 (0.664) for patients who achieved/did not achieve EASI-75, respectively. Patients who achieved EASI-75 had greater reductions in pruritus NRS (-3.76 vs. -1.52), SCORAD VAS sleep loss (-4.05 vs. -2.62), and DLQI (-9.7 vs. -4.7) from baseline to W16, and fewer mean missed days of work/ school (0.77 vs. 4.02) (p < 0.05 for all). A higher proportion of patients who achieved EASI-75 vs. not achieved reported no impairment to certain aspects of patient life on individual DLQI items at W16 (p < 0.05 for all). Conclusions: In this study, achieving EASI-75 corresponded to substantial benefits across multiple aspects of patient burden associated with moderate-to-severe AD. Data first presented at AAD 2017; March 3–7, 2017; Orlando, FL, USA.